OBJECTIVE: To investigate the independent and combined effects of the Trp64Arg polymorphism of the b b 3 -adrenergic receptor (b b 3 AR) gene and the (À3826) A?G polymorphism of the uncoupling protein 1 (UCP1) gene on body weight change in type 2 diabetic and non-diabetic control subjects during a 10 y follow-up study. DESIGN: Controlled 10 y follow-up study with baseline, 5 and 10 y examinations. SUBJECTS: 70 newly diagnosed, middle-aged type 2 diabetic patients and 123 non-diabetic control subjects from eastern Finland. MEASUREMENTS: Anthropometric measurements, blood pressure, oral glucose tolerance test, plasma insulin, plasma C-peptide and HbA 1c . Genotypes by polymerase chain reaction followed by enzymatic digestion. RESULTS: No signi®cant differences were found in the frequencies of the two polymorphisms between diabetic and control subjects. The polymorphisms were not cross-sectionally or longitudinally associated with body weight or BMI in diabetic or control subjects. When the diabetic and control subjects were analysed together, the change in the mean body weight was signi®cantly greater among the subjects with both polymorphisms (n 11) than among those with no polymorphisms (n 103; change in weight 6.5 AE 2.5% vs À0.2 AE 0.8%, P 0.036, and change in Body Mass Index 8.5 AE 2.6% vs 2.0 AE 0.8%, P 0.060, mean AE s.e.m.). CONCLUSIONS: The simultaneous existence of the two polymorphisms was associated with a tendency to gain weight suggesting a synergistic effect of these polymorphisms on body weight gain.
Introduction
The b 3 -adrenergic receptor (b 3 AR) is the major adrenoceptor which stimulates uncoupling protein 1 (UCP1), cyclic adenosine monophosphate (cAMP) acting as a second messenger in brown adipose tissue. 1, 2 Numerous studies concerning the Trp64Arg polymorphism of the b 3 AR gene and its association with body mass index (BMI) and weight gain exist, but the results have been inconsistent. 3, 4 Recent studies on humans have suggested an association between the (À3826) A?G polymorphism of the UCP1 gene and an increased capacity to gain body fat 5 and body weight. 6 An additive effect of the A?G polymorphism of the UCP1 gene and the Trp64Arg polymorphism of the b 3 AR gene on weight gain 6 or weight loss and weight maintenance 7 has also been reported, as well as a synergistic effect of these two polymorphisms contributing to lower basal metabolic rate. 8 The present study assessed the role of these two polymorphisms and their interaction as contributors to body weight changes in Finnish middle-aged, newly diagnosed type 2 diabetic patients, and in non-diabetic control subjects by using data from a 10 y follow-up study.
Study design and methods

Study population
The original study population consisted of 133 newly diagnosed patients with type 2 diabetes (70 men and 63 women), and 144 non-diabetic control subjects (62 men and 82 women), aged 45 ± 64 y at baseline examination carried out between May 1979 and December 1981. Both groups were re-examined after 5 and 10 y during the periods between August 1985 and February 1986, and September 1991 and May 1992. The formation and representativeness of the baseline, 5 and 10 y study populations have been described earlier in detail. 9, 10 Brie¯y, the diabetic patients were referred to the study by general practitioners working in the community health centers of the county of Kuopio in eastern Finland. 9 The diagnosis of diabetes was made in the clinical setting, and it was con®rmed by an oral glucose tolerance test according to WHO diagnostic criteria. 11 The nondiabetic control subjects were randomly selected for the study from the population register of the study area. Approval for the study was given by the ethics committee of the Kuopio University and Kuopio University Hospital. Informed consent was obtained from all the subjects studied.
During the 10 y follow-up, 36 diabetic patients (20 men and 16 women) and eight control subjects (three men and ®ve women) died. In addition, DNA samples were not obtained from all of the original study subjects, and therefore screening for the Trp64Arg polymorphism of the b 3 AR gene and the (À3826) A?G polymorphism of the UCP1 gene was performed in 70 (38 men and 32 women) Type 2 diabetic patients and 123 (55 men and 68 women) non-diabetic control subjects.
Clinical and biochemical characteristics
At baseline, the following examinations were done: clinical history (including data on cardiovascular and other diseases, medication, smoking, and leisure time physical activity), anthropometric measurements, blood pressure, oral glucose tolerance test, and plasma insulin. For the present study, the subjects were classi®ed as physically active during leisure time when they exercised at least three times a week, an exercise period lasting at least 30 min and leading to shortness of breath and need for changing of clothes. At the 5 and 10 y examinations, the measurements done at baseline were repeated, and in addition waist and hip circumferences were measured and plasma Cpeptide and HbA 1c were assessed. The exclusion criteria for the study subjects, as well as the methods for performing the oral glucose tolerance test, and the determinations of glucose, insulin and glycated haemoglobin samples are presented in previous publications. 9, 10 Dietary data At the 10 y examination, quality of dietary fat was examined by a short questionnaire. The quantity, quality, and frequency of use of 19 key food items representing the main sources of dietary fat in Finland 12 were requested. The amount of milk and milk products, meat and meat products, ®sh and poultry, and the fat used on bread were estimated in household measures and with the aid of drawings of portion sizes. The intake of total dietary fat was computed using the Micro-Nutrica dietary analysis programme based on the database of the Finnish Social Insurance Institute. 13 C for 30 s with ®nal extension at 72 C for 4 min. The single base replacement of T by C in codon 64 predicted an amino acid change from tryptophan (TGG) to arginine (CGG). Therefore, ampli®ed exon 1 fragments were digested with BstNI, a restriction enzyme speci®c for the sequence CC(AaT)GG, in a 15 ml volume containing 5 ml of PCR product. The mixture was incubated at 60 C for 1 h. The digested samples were separated on a 3% agarose gel (NuSieve GTG, FMC Bioproducts, Rockland, ME). Digestion of the normal sequence yields fragments of 97, 61, 31, 15 and 6 bp in length, whereas the Trp64Arg mutation eliminates one of the BstNI sites, yielding a novel 158-bp product.
The (À3826) A?G polymorphism in the UCP1 gene was also detected by PCR-RFLP (restriction fragment length polymorphism) methodology as previously described. 8 
Statistical analyses
All calculations were performed using the SPSSaWIN program version 6.0 (SPSS Inc., Chicago, ILL, USA, 1993). Data are presented as meansAE s.d., unless otherwise indicated. Statistical signi®cance of the differences between the groups was evaluated with the chi-square test, ANOVA (followed by post hoc Bonferroni tests), or Student's t-test, when appropriate. Hardy ± Weinberg's equilibrium was tested by the Chi-square test. To control for the effects of diabetesrelated factors, the data were tested by the analysis of covariance (ANCOVA) when analysing the diabetic and control subjects as a combined population.
Results
The characteristics of the study population at the baseline, 5 and 10 y examinations are presented in Table 1 . At baseline, all diabetic patients were treated with diet only. The frequency of drug treatment Weight change and gene polymorphisms K Sivenius et al increased with time: at the 10 y examination, only 15 (21.4%) diabetic subjects were treated with diet only, 46 (65.7%) with oral hypoglycemic drugs, and 9 (12.9%) with insulin.
Among the type 2 diabetic patients, the frequencies of the Trp64Arg polymorphism of the b 3 AR gene and the (À3826) A?G polymorphism of the UCP1 gene did not differ signi®cantly from the control subjects. Ten (14.3%) diabetic and 22 (17.9%) control subjects were carriers of the Trp64Arg polymorphism, whereas 27 (38.6%) diabetic and 42 (34.1%) control subjects had the (À3826) A?G variant allele. Genotype frequencies of these two polymorphisms were found to be in Hardy-Weinberg equilibrium. None of the type 2 diabetic patients or the control subjects were homozygous for the Arg-encoding allele of the b 3 AR gene, whereas one diabetic and two control women were homozygous for the A?G polymorphism of the UCP1 gene (analysed together with the heterozygous subjects).
At the baseline, 5 and 10 y examinations, the Trp64Arg polymorphism of the b 3 AR gene and the A?G polymorphism of the UCP1 gene were not independently associated with sex, body weight, BMI, and fasting plasma glucose and insulin levels in either type 2 diabetic or control subjects (data not shown). Also, no longitudinal association between either of these polymorphisms and the changes in the mean body weight or BMI could be observed.
For further analysis, the diabetic and control subjects were divided into four groups according to their b 3 AR and UCP1 genotype: I Ð no polymorphisms present (NPG); II Ð the Trp64Arg polymorphism only; III Ð the A?G polymorphism only; and IV Ð both polymorphisms present simultaneously (BPG) ( Tables 2 and 3 ). The frequencies of the polymorphisms in the b 3 AR and the UCP1 genes within these four genotype groups did not differ between the diabetic and control subjects.
At the baseline, 5 and 10 y examinations, the BPG diabetic subjects (n 5), as well as the BPG control subjects (n 6) were not signi®cantly different from the rest of the study subjects with respect to sex distribution, body weight, BMI, and concentrations (Tables 2 and 3) . At the 5 and 10 y examinations, no signi®cant differences were observed in concentration of fasting plasma C-peptide and percentage of HbA 1c between the four genotype groups among either diabetic or control subjects. In the control group, the number of subjects with impaired glucose tolerance did not differ signi®cantly between the BPG subjects and the rest of the control subjects at the baseline, 5 or 10 y examinations.
The BPG diabetic subjects had a slight increase in their mean body weight during the 10 y follow-up ( Table 2) , instead of a body weight decrease, which was observed among the other diabetic patients. Furthermore, the BPG control subjects tended to gain more weight than the other control subjects (Table 3) .
For a secondary analysis, the diabetic and control subjects were combined to examine the trend for weight gain in the entire study population. Interestingly, after controlling for the effects of age, sex, glucose tolerance status (type 2 diabetes, IGT or NGT), and antihypertensive and hypoglycemic drug treatment, the change in the mean body weight was signi®cantly greater among the BPG subjects (n 11) than among the NPG subjects (n 103); change in weight 6.5 AE 2.5% vs À0.2 AE 0.8%, P 0.036, and change in BMI 8.5 AE 2.6% vs 2.0 AE 0.8%, P 0.060, mean AE s.e.m.; Figure 1 ). For the subjects having the Trp64Arg polymorphism only, the adjusted changes in the mean weight and BMI were À2.6 AE 2.2% and À1.0 AE 2.3% (meanAE s.e.m.), respectively (Trp64-Arg only vs BPG: P 0.288 for the change in weight, and P 0.273 for the change in BMI). Among the subjects with the A?G polymorphism only, the adjusted changes in the mean weight and BMI were À1.8 AE 1.2% and 0.7 AE 1.3% (mean AE s.e.m.), respectively (A?G only vs BPG: P 0.030 for the change in weight, and P 0.078 for the change in BMI, Figure 1) .
Discussion
In the present study, it was observed by using successive weight measurements that the simultaneous existence of the Trp64Arg polymorphism in the b 3 AR gene and the (À3826) A?G polymorphism in the UCP1 gene was associated with greater weight gain during 10 y of follow-up. This ®nding can be considered as an example of a synergistic effect of two gene polymorphisms on body weight gain.
The frequencies of the two polymorphisms were similar among the type 2 diabetic and non-diabetic control subjects. Also, the frequency of the Trp64Arg polymorphism was similar to those reported in previous studies in Caucasian populations, 15 ± 17 whereas in the present study population the A?G polymorphism was slightly less common than in the study populations reported previously. 5 ± 6,8 In accordance with a growing number of recent studies, 6, 8, 18 we could not ®nd any cross-sectional or longitudinal association between the Trp64Arg polymorphism of the b 3 AR gene and body weight or BMI. Also, in line with previous ®ndings, 8 no associations between the A?G polymorphism of the UCP1 gene and BMI or body weight gain could be observed, although this polymorphism has been suggested to be associated with higher capacity of fat gain over time, 5 as well as high weight gain during adult life. 6 These controversial ®ndings, as well as similar frequencies of the Trp64Arg of the b 3 AR gene and the A?G polymorphism of the UCP1 gene reported among both obese and non-obese subjects, suggest that these genes are not likely to be major independent factors affecting body weight gain or obesity.
However, when the combined effects of the Trp64Arg and the (À3826) A?G polymorphisms were examined, it was observed that the body weight gain was greater among the study subjects with simultaneous occurrence of the two polymorphisms than among other study subjects. This ®nding was consistent in both non-diabetic and diabetic subjects, but in diabetic subjects with these two polymorphisms the weight gain was only minor, probably due to the active effort loosing weight or diabetesrelated factors. Importantly, no difference in glucose tolerance deterioration that could have an impact on body weight was observed between the two diabetic genotype groups during the 10 y follow-up.
Similarly, an additive effect of the A?G and Trp64Arg polymorphisms on weight gain in morbid obesity has been observed, 6 as well as a synergistic effect of these polymorphisms contributing to lowered basal metabolic rate in obese Finns. 8 The results of the present long-term study are in agreement with these earlier ®ndings and strengthen the synergistic effect of these two polymorphisms acting on body weight regulation.
In addition to the possible genetic factors, body weight may be in¯uenced by several other factors, eg Figure 1 The change in the mean weight during the 10 y followup in type 2 diabetic and non-diabetic control subjects (combined) according to the Trp64Arg and the (À3826) A?G polymorphisms in the b 3 AR and UCP1 genes. u both polymorphisms present; j no polymorphisms present; e the A?G polymorphism only; s the Trp64Arg polymorphism only.
Weight change and gene polymorphisms K Sivenius et al diet, physical activity, medication, and smoking. In the present study, the use of b-blocking agents and diuretics for the treatment of hypertension, as well as smoking history, daily intake of fat, and leisure time physical activity were not signi®cantly different between those with both polymorphisms present and the rest of the diabetic or control subjects. Despite of a large number of studies concerning the Trp64Arg and A?G polymorphisms. only a little is, known about the functional effects of these polymorphisms. Recently Hoffstedt et al reported an association between the b 3 -Arg haplotype and a marked decrease in b 3 -adrenoreceptor function. 19 The A?G polymorphism of the UCP1 gene has been associated with lower UCP1 mRNA levels in intraperitoneal adipose tissue of obese subjects, whereas in the same study the Trp64Arg polymorphism displayed no signi®cant association with UCP1 mRNA expression levels. 20 The results of the current study are based on quite a small number of individuals and, furthermore, the results are not supported by data concerning differences in basal metabolic rate, body composition, or b 3 -adrenergic receptor function. Therefore, the interpretation of data should be done with caution. However, the strength of the present study lies in the long follow-up time as well as in the good characterization of the study population.
In conclusion, the Trp64Arg polymorphism of the b 3 AR gene and the (À3826) A?G polymorphism of the UCP1 gene are not major independent factors for body weight gain and obesity in Finnish subjects. However, in the present study, the simultaneous occurrence of these two polymorphisms predicted greater weight gain, suggesting a synergistic effect of the Trp64Arg polymorphism in the b 3 AR gene and the A?G polymorphism in the UCP1 gene on body weight gain.
Abbreviations b 3 AR, b 3 -adrenergic receptor; UCP1, uncoupling protein 1; cAMP, cyclic adenosine monophosphate; PCR, polymerase chain reaction; BPG, both polymorphisms group; NPG, no polymorphisms group; IGT, impaired glucose tolerance; NGT, normal glucose tolerance
